Serotonin reuptake inhibitors
AssigneeTheravance, Inc.
InventorsEric L. Stangeland, Lori Jean Patterson, Daisuke Roland Saito
Life of this patent
Estimating the term…
Abstract
In one aspect, the invention relates to compounds of formula I: where X, Y, R1, R2, R3, R4, R4, and n are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
Claims21
(canceled)
The method of claim 22, where R1 is selected from methyl, ethyl, isopropyl, —(CH2)2NHC(O)CH3, —(CH2)2OH, —(CH2)C(O)OCH3, phenyl, 4-phenylacetamide, and 4-pyridyl.
The method of claim 22, where R2 is hydrogen.
The method of claim 22, where R3 is selected from hydrogen and cyano.
The method of claim 22, where R4 is selected from halo, —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms, —O—C1-6alkyl optionally substituted with 1 to 5 fluoro atoms, and —NO2.
The method of claim 22, where n is 1.
The method of claim 22, where X and Y are —CH—.
The method of claim 22, where X is —CH— and Y is —N—.
The method of claim 22, where X is —N— and Y is —CH—.
The method of claim 22, wherein the compound of formula I has a configuration selected from:
- or is enriched in a stereoisomeric form having said configuration.
The method of claim 22, wherein the compound of formula I has a configuration selected from:
- or is enriched in a stereoisomeric form having said configuration.
18-21. (canceled)
A method of treating pulmonary arterial hypertension, comprising administering to a patient a therapeutically effective amount of a compound of formula I:
- where:
- X and Y are —CH—, or X is —CH— and Y is —N—, or X is —N— and Y is —CH—;
- R1 is selected from —C1-6alkyl optionally substituted with 1 to 5 groups selected from halo, —NHC(O)CH3, and —C(O)NHCH3;
- —C3-6cycloalkyl;
- —C1-2alkylene-OR;
- —C1-2alkylene-COOR;
- —C0-3alkylene-phenyl optionally substituted with —NHC(O)CH3 or —C(O)NHCH3;
- and —C0-3alkylene-pyridyl;
- where R is selected from hydrogen and —C1-3alkyl;
- R2 is selected from hydrogen, —C1-6alkyl, and —O—C1-6alkyl;
- R3 is selected from hydrogen, halo, and cyano;
- R4 is selected from halo;
- —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms;
- —O—C1-6alkyl optionally substituted with 1 to 5 fluoro atoms;
- —C0-1alkylene-phenyl;
- —O—C0-3alkylene-phenyl;
- —SO2—C1-6alkyl;
- —C(O)NH2;
- and —NO2;
- and
- n is 1 or 2;
- or a pharmaceutically acceptable salt thereof.
(canceled)
A method of treating a patient that is in need of anti-platelet therapy, comprising administering a therapeutically effective amount of a compound of formula I:
- where:
- X and Y are —CH—, or X is —CH— and Y is —N—, or X is —N— and Y is —CH—;
- R1 is selected from —C1-6alkyl optionally substituted with 1 to 5 groups selected from halo, —NHC(O)CH3, and —C(O)NHCH3;
- —C3-6cycloalkyl;
- —C1-2alkylene-OR;
- —C1-2alkylene-COOR;
- —C0-3alkylene-phenyl optionally substituted with —NHC(O)CH3 or —C(O)NHCH3;
- and —C0-3alkylene-pyridyl;
- where R is selected from hydrogen and —C1-3alkyl;
- R2 is selected from hydrogen, —C1-6alkyl, and —O—C1-6alkyl;
- R3 is selected from hydrogen, halo, and cyano;
- R4 is selected from halo;
- —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms;
- —O—C1-6alkyl optionally substituted with 1 to 5 fluoro atoms;
- —C0-1alkylene-phenyl;
- —O—C0-3alkylene-phenyl;
- —SO2—C1-6alkyl;
- —C(O)NH2;
- and —NO2;
- and
- n is 1 or 2;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.